https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=Iterum_Therapeutics_plcIterum Therapeutics plc - Revizia istoricului2026-04-04T17:48:38ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=Iterum_Therapeutics_plc&diff=426099&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei Iterum Therapeutics plc listata cu simbolul US.ITRM ==Descriere companie== Iterum Therapeutics PLC (http://www.iterumtx.com/) is a clinical-stage pharmaceutical company. The Company is focused on developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens. The Company is developing sulopenem - the oral and intervenous (IV) penem antibiotic demonstrating a potent spectrum of ac...2024-09-18T18:05:53Z<p>Pagină nouă: Pagina dedicata companiei Iterum Therapeutics plc listata cu simbolul US.ITRM ==Descriere companie== Iterum Therapeutics PLC (http://www.iterumtx.com/) is a clinical-stage pharmaceutical company. The Company is focused on developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens. The Company is developing sulopenem - the oral and intervenous (IV) penem antibiotic demonstrating a potent spectrum of ac...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei Iterum Therapeutics plc listata cu simbolul US.ITRM<br />
<br />
==Descriere companie==<br />
Iterum Therapeutics PLC (http://www.iterumtx.com/) is a clinical-stage pharmaceutical company. The Company is focused on developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens. The Company is developing sulopenem - the oral and intervenous (IV) penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative. It is a bioavailable, antibiotic covering gram-positive, gram-negative and anaerobic pathogen with in-vitro activity against multidrug-resistant pathogens, including Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia, coli and Klebsiella and pneumonia. The Company also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid, which is known as oral sulopenem.<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.ITRM" /><br />
<br />
==Ultimele stiri despre Iterum Therapeutics plc (US.ITRM)==<br />
<dynamicpagelist><br />
category=US.ITRM<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.ITRM]][[Categorie:Stiri despre companii]]</div>Admin